Human kallikrein 8 (hK8/TADG-14) expression is associated with an early clinical stage and favorable prognosis in ovarian cancer

  • Authors:
    • Kazushi Shigemasa
    • Xiurong Tian
    • Lijun Gu
    • Hirotoshi Tanimoto
    • Lowell J. Underwood
    • Timothy J. O'Brien
    • Koso Ohama
  • View Affiliations

  • Published online on: June 1, 2004     https://doi.org/10.3892/or.11.6.1153
  • Pages: 1153-1159
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The purpose of this study was to examine human kallikrein 8 (hK8/TADG-14) expression in epithelial ovarian tumors and to investigate the association of hK8 expression levels with patient survival. Human kallikrein 8 protein (hK8) expression was examined by immunohistochemistry in 74 ovarian adenocarcinomas and 6 normal ovaries. Results of immunostaining were correlated with clinicopathological variables and overall survival of the patients. Human kallikrein 8 gene (KLK8) mRNA expression was examined by semi-quantitative PCR in 35 ovarian tumors and 7 normal ovaries. Expression of hK8 was not detected on the surface epithelium of normal ovaries. In contrast, hK8 expression was detected in 51.4% (38/74) of carcinomas with a significantly higher detection rate of hK8 expression being observed in early stage disease compared to advanced stage disease (p=0.0192). Data analysis using the log-rank test showed hK8 expression correlated significantly with favorable patient survival (p=0.0328). Younger age (p=0.0008), early clinical stage (p<0.0001), and low histological grades of the tumors (p=0.0018) were also associated significantly with a favorable prognosis. In a multivariate model, age (p=0.0186) and clinical stage (p<0.0001) remained associated significantly with overall survival, whereas hK8 expression and histological grade lost their significance. There was significant relationship between the hK8 expression status and KLK8 mRNA expression levels (p=0.0304). Expression of hK8 is increased during the development of ovarian cancer and down-regulated during ovarian cancer progression. Expression of hK8 is a favorable prognostic marker in patients with ovarian cancer.

Related Articles

Journal Cover

June 2004
Volume 11 Issue 6

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Shigemasa K, Tian X, Gu L, Tanimoto H, Underwood LJ, O'Brien TJ and Ohama K: Human kallikrein 8 (hK8/TADG-14) expression is associated with an early clinical stage and favorable prognosis in ovarian cancer. Oncol Rep 11: 1153-1159, 2004.
APA
Shigemasa, K., Tian, X., Gu, L., Tanimoto, H., Underwood, L.J., O'Brien, T.J., & Ohama, K. (2004). Human kallikrein 8 (hK8/TADG-14) expression is associated with an early clinical stage and favorable prognosis in ovarian cancer. Oncology Reports, 11, 1153-1159. https://doi.org/10.3892/or.11.6.1153
MLA
Shigemasa, K., Tian, X., Gu, L., Tanimoto, H., Underwood, L. J., O'Brien, T. J., Ohama, K."Human kallikrein 8 (hK8/TADG-14) expression is associated with an early clinical stage and favorable prognosis in ovarian cancer". Oncology Reports 11.6 (2004): 1153-1159.
Chicago
Shigemasa, K., Tian, X., Gu, L., Tanimoto, H., Underwood, L. J., O'Brien, T. J., Ohama, K."Human kallikrein 8 (hK8/TADG-14) expression is associated with an early clinical stage and favorable prognosis in ovarian cancer". Oncology Reports 11, no. 6 (2004): 1153-1159. https://doi.org/10.3892/or.11.6.1153